NCT05623059

Evaluate Pharmacokinetics and Safety of Slow Release DHEA

Phase IIa Clinical Trial to Evaluate Pharmacokinetics and Safety of Slow Release DHEA

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 18 (actual)
• Sponsor: Indiana University · Academic / Other
• Sex: All
• Age: 18 Years – 50 Years
• Healthy volunteers: Not accepted

Summary

This is a study to look at pharmacokinetic levels of different doses of slow release DHEA in subjects with asthma.

Detailed description

Pharmacokinetic (PK) studies of DHEA in asthma have never been done. In many diseases, PK in subjects with disease differs from that of control subjects and those with other conditions. Therefore, researchers are investigating if PK levels of slow release DHEA are different in subjects with asthma who have the HSD3B1 AA or AC phenotypes

Conditions

• Asthma
• Genotype

Interventions

Type	Name	Description
DRUG	Slow Release DHEA	DHEA is a hormone produced by the body's adrenal gland. In drug form, it is available as an over-the-counter supplement that is available on the market without prescription.

Timeline

• Start date: 2023-03-03
• Primary completion: 2025-04-24
• Completion: 2025-04-24
• First posted: 2022-11-21
• Last updated: 2025-07-10

Locations

2 sites across 1 country: United States

Regulatory

• FDA-regulated drug study